Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. EAT

Go back to Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease

BTIG on Opus Genetics (IRD): 'the path from here to BLA submission seems clear'

July 6, 2026 12:06 PM EDT

BTIG analyst Thomas Shrader reiterated a Buy rating and $12.00 price target on Opus Genetics (NASDAQ: IRD).

The analyst comments "Another turn of the crank in Opus' relentless drive to get a half dozen gene replacement therapies approved for IRDs (Exhibit 1 is the named pipeline, but there are several more floating around the academic world Opus may grab as cash allows). Each story is backed by a predictive animal model and the constructs are already built with regulatory elements either used in approved LUXTURNA (safe, life changing and stable for a decade and... More